Novartis Second Quarter and Half Year 2025 Condensed Interim Financial Report – Supplementary Data Operating performance review | INDEX | Page | | --- | --- | | OPERATING PERFORMANCE REVIEW | 3 | | CASH FLOW AND BALANCE SHEET | 10 | | INNOVATION REVIEW | 14 | | CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS | | | Consolidated income statements | 16 | | Consolidated statements of comprehensive income | 18 | | Consolidated balance sheets | 19 | | Consolidated statements of changes in equity | 20 | | Cons ...

诺华制药首席执行官表示将在美国进行230亿美元的新投资。 ...

智通财经7月17日电，诺华制药首席执行官表示将在美国进行230亿美元的新投资。 ...

诺华制药股价在公布业绩后下跌1.25%。沃尔沃股价上涨2.7%。 ...

Novartis raises its profit outlook after reporting better-than-expected results for the latest quarter https://t.co/AYTv5NuA6B ...

诺华制药表示，启动最高100亿美元的 股票回购计划， 回购计划预计2027年底前完成。 ...

Group 1 - The core viewpoint of the article is that Novartis expects to achieve high single-digit growth in net sales by 2025 [1] Group 2 - The company is projecting a positive sales trajectory, indicating confidence in its product pipeline and market strategies [1]

Core Viewpoint - Novartis has announced the appointment of Mukul Mehta as the new Chief Financial Officer (CFO), effective March 16, 2026, succeeding Harry Kirsch, who will retire after a 22-year career with the company [1][6]. Group 1: Leadership Transition - Mukul Mehta brings over 20 years of experience at Novartis, having held various key finance leadership roles, including CFO International and CFO Pharmaceuticals [3][6]. - Harry Kirsch has been with Novartis for 22 years and has played a significant role in the company's transformation, including streamlining divisions and successful spinoffs [2][4]. - Mukul Mehta expressed his honor in taking on the CFO role and emphasized the commitment to delivering sustainable value for patients and shareholders [4]. Group 2: Company Performance - Under Harry Kirsch's leadership, Novartis has seen significant improvements in financial performance, including a strong balance sheet and robust free cash flow [4]. - The company has transitioned from six divisions to three and successfully divested stakes in various ventures, enhancing its focus on medicines [2][4]. Group 3: Future Outlook - Mukul Mehta's deep knowledge of the business and strong financial expertise are expected to guide Novartis through its next phase of growth [4]. - The company aims to continue its journey as a focused medicines company, enhancing its impact on patients and shareholders [4].

智通财经7月17日电，诺华第二季度销售净额140.5亿美元，预估140.4亿美元；核心净利润47.1亿美元， 预估46.2亿美元；核心每股收益2.42美元，预估2.34美元。 ...

Core Viewpoint - Novartis reported strong Q2 2025 results with double-digit growth in net sales and core operating income, driven by successful product launches and pipeline advancements, alongside a commitment to a significant share buyback program [3][4][5]. Financial Performance - Q2 2025 net sales reached USD 14.1 billion, a 12% increase year-over-year, with constant currency growth of 11% [4][30]. - Operating income for Q2 2025 was USD 4.9 billion, reflecting a 21% increase, while net income rose to USD 4.0 billion, up 24% [4][9]. - Core operating income was USD 5.9 billion, a 20% increase, with a core operating income margin of 42.2% [10][30]. - Free cash flow for Q2 2025 was USD 6.3 billion, a 37% increase compared to the previous year [10][30]. - For H1 2025, net sales totaled USD 27.3 billion, up 12%, and core operating income increased by 21% to USD 11.5 billion [11][13]. Product Performance - Key growth drivers included Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc), and Pluvicto (+30% cc) [5][16]. - The top 20 brands generated USD 11.6 billion in Q2 2025, with a 16% increase year-over-year [17][18]. Strategic Initiatives - Novartis announced an up-to USD 10 billion share buyback program to enhance shareholder returns [3][5]. - The company raised its full-year 2025 guidance for core operating income growth to low teens, while maintaining high single-digit sales growth expectations [5][28]. Research and Development - Significant pipeline milestones included positive Phase III results for Pluvicto in hormone-sensitive prostate cancer and FDA approval for Vanrafia for IgAN [5][19][21]. - Ongoing trials and studies showed promising results for various therapies, including Kisqali and Scemblix, with plans for further regulatory submissions [22][23]. Capital Structure - As of June 30, 2025, net debt increased to USD 23.8 billion, primarily due to cash outflows for dividends and share repurchases [26]. - The company maintains a strong capital structure with a focus on balanced capital allocation [24][25].